Merck signs up Abbott to develop companion Dx for unnamed cancer drug
This article was originally published in Scrip
Executive Summary
Marking the latest deal in the increasingly popular companion diagnostics space, Abbott has agreed to provide a test to aid the development of an unnamed cancer drug being developed by Merck & Co. Financial terms of the deal were not disclosed.